Evidence map›Paper›PMID 34410950›Full record

ArticleIn vivo (Athens, Greece)

The Expression of NRIP1 and LCOR in Endometrioid Endometrial Cancer.

Stefanos Flindris, Nikolaos Katsoulas, Anna Goussia, Andreas Christos Lazaris, Iordanis Navrozoglou, Minas Paschopoulos, Irene Thymara

Open access · diamondAbstract read
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Stefanos FlindrisDepartment of Obstetrics and Gynecology, University Hospital of Ioannina, Ioannina, Greece; stefflindris@gmail.com.
Nikolaos KatsoulasFirst Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital of Athens, Athens, Greece.
Anna GoussiaDepartment of Pathology, University Hospital of Ioannina, Ioannina, Greece.
Andreas Christos LazarisFirst Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital of Athens, Athens, Greece.
Iordanis NavrozoglouDepartment of Obstetrics and Gynecology, University Hospital of Ioannina, Ioannina, Greece.
Minas PaschopoulosDepartment of Obstetrics and Gynecology, University Hospital of Ioannina, Ioannina, Greece.
Irene ThymaraFirst Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital of Athens, Athens, Greece.
University Hospital of Ioannina · GRLaiko General Hospital of Athens · GRNational and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of the study was to analyze the expression of nuclear receptor interacting protein 1 (NRIP1) and its partner ligand-dependent nuclear receptor co-repressor (LCOR) in endometrioid endometrial cancer and to investigate their association with estrogen receptor (ER), progesterone receptor (PR), Ki-67, clinicopathological parameters and patient survival. MATERIALS AND

methodsImmunohistochemical evaluation was carried out to investigate the subcellular expression of NRIP1 and LCOR in endometrioid endometrial cancer samples. Statistical analysis was used to identify the correlations of NRIP1 and LCOR expression with clinicopathological variables and to estimate the survival rates.

resultsEndometrial cancer tissues exhibited higher expression of NRIP1 and LCOR in comparison with the normal tissues. Cytoplasmic LCOR expression was positively associated with ER and PR expression, while cytoplasmic NRIP1 expression was positively associated with ER expression. Moreover, cytoplasmic expression of NRIP1 was positively associated with Ki-67.

conclusionOur study demonstrated that high cytoplasmic expression of LCOR may predict a longer overall survival of patients with endometrioid endometrial cancer. Patients with tumors expressing low levels of LCOR showed a worse survival compared to those expressing high levels.

Indexed as

Carcinoma, EndometrioidEndometrial NeoplasmsBiomarkers, TumorFemaleHumansNuclear Receptor Interacting Protein 1Receptors, EstrogenReceptors, ProgesteroneRepressor ProteinsBiomarkers, TumorLCOR protein, humanNRIP1 protein, humanNuclear Receptor Interacting Protein 1Receptors, EstrogenReceptors, ProgesteroneRepressor ProteinsEndometrioid endometrial cancerERLCORNRIP1PR

Identifiers

PMID34410950
PMCPMC8408693
OpenAlexW3193846217

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.